COVID-19 vaccines to market.Acuitas Therapeutics is currently partnering with three teams, including one backed by drug giant Pfizer and one out of Imperial College London, who have entered Phase I/II clinical vaccine trials.BioNTech, which has partnered with Pfizer, began its trials back in April, while CureVac and Imperial College began trials last month.
Potential coronavirus vaccine has ‘right sort of immune response’ in trial: scientist Acuitas president Tom Madden says researchers are hoping to use Messenger RNA to create an immune response that defends against COVID-19.Acuitas’ role in the vaccines is the creation of a delivery method to get that material into the body.“We provide microscopic carriers, lipid nanoparticles, that.